This is a clip by Dr. David Bauer. He is a lead on a study that he's going to be talking

about, but he's he's heads up the RNA virus replication laboratory at the Francis Crick

Institute. And here's what he had to say about immunity and vaccination. Take a look.

Okay. So the key message from our finding is that we found that recipients of the Pfizer

vaccine, those who've had two doses, have about five to sixfold lower amounts of neutralizing

antibodies. Now these are the sort of gold standard private security antibodies of your

immune system, which block the virus from getting into your cells in the first place.

So we found that that's less for people with two doses. We've also found that for people

with only one dose of the Pfizer jab that they are less likely to have high levels of these

antibodies in their blood. And perhaps most importantly for all of us going forward is that

we see that the older you are, the lower your levels are likely to be. And the time since

you've had your second jab, as that time goes on, the lower your levels are also likely

to be. So that's telling us that we're probably going to be needing to prioritize boosters

for older and more vulnerable people coming up soon, especially if this new variant spreads.

Boy, not very good news from an MRNA specialist right there.

Boosters are coming. And what else he found in that study was the increase of a person's

age and also the time that is elapsed after their second booster correlated with a decrease

in activity of those neutralizing antibodies for not only the Delta variant, but the beta

variant, which we used to be called the South African variant. So there's two of them there.

And obviously they called for boosters at the end of that study. But you know, science

is acting like this is a big shock. Like these are new findings. But again, if anybody's

been watching the high wire, we covered this back in August of 2020. Take a look at this.

...